Intec Closes Merger with Decoy Biosystems
USA - English
Changes Corporate Name to Indaptus Therapeutics to Reflect Clinical Focus
News provided by
Share this article
Share this article
NEW YORK, Aug. 3, 2021 /PRNewswire/ Indaptus Therapeutics, Inc. (Nasdaq: INDP) ( Indaptus or the Company, and formerly, Intec Parent, Inc.) today announced the closing of its previously announced merger with Decoy Biosystems, Inc. ( Decoy ) and the completion of a $30 million private placement in accordance with the merger agreement. In addition, the Company announced a corporate name change to Indaptus Therapeutics, as it better reflects the Company s therapeutic focus.
Indaptus is expected to begin trading on the Nasdaq Capital Market at the open of trading on August 4, 2021, under the ticker symbol INDP and a new CUSIP number (45339J 105). The previous ticker symbol was NTEC (Nasdaq: NTEC). The Company will have a new website address: www.indaptusrx.com.
Israel
Israeli
Jeffrey-meckler
Anthonyj-maddaluna
Hoonmo-lee
Hila-karah
Wintec-pharma
Roger-pomerantz
Brian-ocallaghan
Michaelj-newman
Nir-sassi
Walt-linscott